$4.47
▼ -0.2% Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Overview
52-week range
$1.62
$5.05
83% of range
Avg surprise (last 1)
+20.0%
Avg reaction (last 2)
+4.0%
100% positive
Latest IV / EM
108%
EM ±24.7% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.04 | $-0.05 | +20.0% | +88.2% | +2.2% | earnings |
| Mon Aug 18, 2025 | Jun/2025 | $-0.98 | — | — | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.34 | — | — | — | +5.7% | earnings |
| Sun Mar 31, 2024 | Mar 2024 | $-0.74 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.07 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.12 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 17, 2026 | Jun/2026 | OTHER | -$0.09 | -$0.98 | +90.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | — | $242,000 | — | $0 | — | $0 | — |
| Cost of revenue | $631,000 | — | $97,000 | — | $0 | — | $0 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-5M | — | $-4M | $-4M | $-4M | — | $-3M | $-7M |
| Net income | $-1M | — | $-6M | $-18M | $-6M | — | $-2M | $-8M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7M | $8M | $7M | $3M | $6M | $1M | $2M | $2M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $7M | $9M | $12M | $5M | $7M | $3M | $4M | $5M |
| Total assets | $12M | $13M | $15M | $5M | $8M | $4M | $4M | $5M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $26M | $29M | $41M | $40M | $33M | $27M | $23M | $24M |
| Total equity | $-14M | $-16M | $-26M | $-36M | $-25M | $-23M | $-19M | $-18M |